SARS-CoV-2 vaccination in heart transplantation: What we do and do not know
- PMID: 34876356
- PMCID: PMC8566197
- DOI: 10.1016/j.healun.2021.10.017
SARS-CoV-2 vaccination in heart transplantation: What we do and do not know
Conflict of interest statement
Disclosure statement Michael G Ison reports research support, paid to Northwestern University, from AiCuris, GlaxoSmithKline, Janssen and Shire; he is a paid consultant for Adagio, AlloVir, Celltrion, Cidara, Genentech, Roche, Janssen, Shionogi, Viracor Eurofins; he is also a paid member of DSMBs from Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda and Vitaeris. Saima Aslam reports grant funding from the Cystic Fibrosis Foundation; she is also a consultant for Merck (honoraria received), Gilead (honoraria received), and BioMx (unpaid).
Comment on
-
BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.J Heart Lung Transplant. 2021 Aug;40(8):759-762. doi: 10.1016/j.healun.2021.04.003. Epub 2021 Apr 21. J Heart Lung Transplant. 2021. PMID: 34034958 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
